Ian Odell is a Dermatology physician affiliated with Yale University. OpenAlex indexes 54 publications with 1,447 citations (h-index 13).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
333 Cedar St Bldg Lmp
Room 5040
New Haven, CT 065103206
Telephone
203-785-4092Registry record last updated 2 May 2016.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novartis Pharmaceuticals CorporationProgram year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Dermatology
25.5%Corticosteroid17.6%Triamcinolone Acetonide100%Part D≥56 patientsInterleukin-4 Receptor alpha Antagonist5.2%Dupixent Syringe100%Part D<11 patients+ 1 more class in this area
Sensory organs
23.3%Corticosteroid23.3%Clobetasol Propionate46%Hydrocortisone42%Betamethasone Dipropionate13%Part D<11 patientsCancer & immunology
17.3%Interleukin-23 Antagonist4.7%Skyrizi Pen100%Part D<11 patientsKinase inhibitor3.5%Opzelura100%Part D<11 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2021–2025 per NIH RePORTER. The latest:
- Epidermal Growth Factor Receptor Signaling in Fibrotic Skin Disease
Yale University
FY2025$172,260K08AR077689 - Epidermal Growth Factor Receptor Signaling in Fibrotic Skin Disease
Yale University
FY2024$172,260K08AR077689
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
John Krystal, MD
Yale University
Lajos Pusztai, MD
Yale University
Lee Schwamm, MD
Yale University
Naftali Kaminski, MD
Yale University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”